Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular cancer, 2018 - Springer
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
S Wang, S Cang, D Liu - Journal of hematology & oncology, 2016 - Springer
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are
widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M …
widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M …
Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry
X Lu, L Yu, Z Zhang, X Ren, JB Smaill… - Medicinal research …, 2018 - Wiley Online Library
Both the first‐generation reversible epidermal growth factor receptor (EGFR) inhibitors
gefitinib and erlotinib and the second‐generation covalent epidermal growth factor receptor …
gefitinib and erlotinib and the second‐generation covalent epidermal growth factor receptor …
[HTML][HTML] Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
I Sullivan, D Planchard - Frontiers in medicine, 2017 - frontiersin.org
Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
BC Liao, CC Lin, JH Lee, JCH Yang - Journal of biomedical science, 2016 - Springer
The first-and second-generation epidermal growth factor receptor tyrosine kinase inhibitors
(1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as standard first …
(1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as standard first …
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
BC Liao, CC Lin, JH Lee, JCH Yang - Lung Cancer, 2017 - Elsevier
The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),
gefitinib and erlotinib, and the second-generation EGFR-TKI, afatinib, have all been …
gefitinib and erlotinib, and the second-generation EGFR-TKI, afatinib, have all been …
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
K Ninomiya, K Ohashi, G Makimoto, S Tomida… - Scientific reports, 2018 - nature.com
As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
(TKI), osimeritnib is the standard treatment for patients with non-small cell lung cancer …
(TKI), osimeritnib is the standard treatment for patients with non-small cell lung cancer …
Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
PN Tran, SJ Klempner - Lung Cancer: Targets and Therapy, 2016 - Taylor & Francis
Patients with non-small-cell lung cancer (NSCLC) harboring activating mutations in EGFR
benefit from treatment with EGFR small-molecule tyrosine-kinase inhibitors. However, the …
benefit from treatment with EGFR small-molecule tyrosine-kinase inhibitors. However, the …
Cysteine-targeted irreversible inhibitors of tyrosine kinases and key interactions
C Hu, X Dong - Current Medicinal Chemistry, 2019 - ingentaconnect.com
Tyrosine kinases are a subgroup of a large class of protein kinases that transfer phosphate
groups from ATP to various amino acid residues. By phosphorylating the tyrosine residues …
groups from ATP to various amino acid residues. By phosphorylating the tyrosine residues …
Targeted Therapies Used in the Treatment of Non–Small-Cell Lung Cancer: An Overview
T Yadav, V Mehta, N Bhusare, M Chintamaneni… - Drug Repurposing for …, 2023 - Springer
Non-small cell lung cancer (NSCLC) is one of the highest killer disease in the world among
all cancers. It is found that the survival rate after the treatment for NSCLC is lesser compared …
all cancers. It is found that the survival rate after the treatment for NSCLC is lesser compared …